Inhibrx Biosciences stock
INBXNASDAQInhibrx Biosciences Inc., HealthcareISIN US45720N1037
34Score 34 out of 100, Weak
Price and trend
63 / 100
Price history
+16% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 2.1% below it.
Since July 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 36% below its 52-week high. Largest decline in 6 years: 83% (December 2020 to June 2022).
Chart figures for advanced users
- SMA 50$96.79
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$92.57
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$58.39
- The lowest closing price of the last twelve months.
- Resistance$141.84
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Inhibrx Biosciences Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.33B, is number 168 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.3M (up 550% year on year) and a loss of $140.06M.
- MEQIRI Score 34 out of 100 (Weak): rank 648 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $124.22M, financial debt $107.01M.
Weaknesses
- High debtDebt 13.39 times equity (latest quarter), Biotechnology median 0.09.Stability 26
- Revenue shrinkingRevenue down 36.7% a year since 2020.Growth 32
- Loss-makingLoss of $140.06M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 33 to 34.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Revenue has declined since 2016 (-17% per year), so it is worth watching closely.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −91%, operating −10387%, net −10773%. Last 12 months: net 0%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 13 Nov 2026tomorrow
- Last reported
- 13 Aug 2026EPS reported −$2.34 (expected −$2.28)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$9.520.0%
- Revenue
- $4.3M0.0%
- Earnings per share
- −$8.940.0%
- Revenue
- $36.07M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
3 insiders bought on the open market between 8 Sept 2026 and 28 Sept 2026, $5.5M in total. One insider sold, $279,010 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Lappe MarkPurchase
14 Oct 2026, Chief Executive Officer
- Shares
- 10,040
- Price
- $84.56
- Value
- $848,977
- Lappe MarkPurchase
28 Sept 2026, Chief Executive Officer
- Shares
- 4,500
- Price
- $100.76
- Value
- $453,426
- Lappe MarkPurchase
25 Sept 2026, Chief Executive Officer
- Shares
- 5,500
- Price
- $99.16
- Value
- $545,357
Show 10 more
- Kayyem Jon FaizPurchase
23 Sept 2026, Board
- Shares
- 5,000
- Price
- $100.00
- Value
- $500,000
- Kayyem Jon FaizPurchase
16 Sept 2026, Board
- Shares
- 5,000
- Price
- $100.00
- Value
- $500,000
- Manhard KimberlySale
15 Sept 2026, Board
- Shares
- 500
- Price
- $105.05
- Value
- $52,525
- Manhard KimberlySale
14 Sept 2026, Board
- Shares
- 500
- Price
- $110.26
- Value
- $55,130
- Manhard KimberlySale
11 Sept 2026, Board
- Shares
- 500
- Price
- $111.78
- Value
- $55,888
- Manhard KimberlySale
9 Sept 2026, Board
- Shares
- 500
- Price
- $115.80
- Value
- $57,898
- Manhard KimberlySale
8 Sept 2026, Board
- Shares
- 500
- Price
- $115.14
- Value
- $57,570
- Kayyem Jon FaizPurchase
8 Sept 2026, Board
- Shares
- 5,000
- Price
- $113.52
- Value
- $567,580
- Forsyth DouglasPurchase
8 Sept 2026, Board
- Shares
- 2,500
- Price
- $114.65
- Value
- $286,617
- Lappe MarkPurchase
8 Sept 2026, Chief Executive Officer
- Shares
- 25,000
- Price
- $105.82
- Value
- $2.65M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Inhibrx Biosciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Ascentage Pharma Group InternationalAAPG $1.39B37
- MannKindMNKD $1.35B39
- InnovivaINVA $1.34B67
- Pharma MarPHM.MC $1.34B59
- GH ResearchGHRS $1.32B37
- COMPASS PathwaysCMPS $1.32B35
- OmerosOMER $1.31B52
- IdorsiaIDIA.SW $1.3B36
ETFs that hold Inhibrx Biosciences
Held by 8 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.08% | 0.35% | €1.21B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
Show 4 more
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.00% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Aug 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.